Elekta

54.60 SEK

+0.55 %

Less than 1K followers

EKTA B

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

+0.55 %

+1.49 %

-10.20 %

-3.79 %

+9.42 %

+9.42 %

-35.19 %

-52.34 %

+525.90 %

Elekta operates in the medical technology industry and focuses on the development, manufacture and distribution of medical equipment for cancer treatment and neurosurgery. The company's products include radiotherapy machines and diagnostic imaging systems. The business has a global market position. Elekta was founded in 1972 and is headquartered in Stockholm.

Market cap

20.94B SEK

Turnover

54.03M SEK

Revenue

18.02B

EBIT %

4.94 %

P/E

88.06

Dividend yield-%

4.4 %

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

28.5

2026

Annual report '26

27.8

2026

Interim report Q1'27

3.9

2026

General meeting '26

All

Press releases

ShowingAll content types

Press release4/17/2026, 5:00 AM

Invitation to Elekta's Capital Markets Day on June 17, 2026

Regulatory press release3/5/2026, 6:30 AM

Third quarter, November–January 2025/26

Regulatory press release2/25/2026, 6:30 AM

Change in Elekta’s Nomination Committee for the Annual General Meeting 2026

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release2/19/2026, 6:30 AM

Invitation to Elekta’s Q3 2025/26 call at 9:00 a.m. CET, March 5

Press release1/30/2026, 11:00 AM

Elekta presents Strategic Update: growth, innovation, and operations

Press release1/23/2026, 10:10 AM

Elekta appoints Tomas Eliasson as Vice Chair of the Board

Regulatory press release1/16/2026, 8:54 AM

Elekta receives FDA 510(k) clearance for Elekta Evo linear accelerator

Press release1/12/2026, 9:00 AM

Invitation to Elekta's Strategic Update event on January 30

Regulatory press release11/26/2025, 6:30 AM

Second quarter, August–October 2025/26

Press release11/12/2025, 6:30 AM

Invitation to the presentation of Elekta’s second quarter 2025/26

Regulatory press release10/31/2025, 6:30 AM

Elekta’s Nomination Committee for the Annual General Meeting 2026

Press release10/9/2025, 5:30 AM

New impact report reveals radiotherapy’s role in cancer care

Press release9/29/2025, 6:10 PM

Study shows MRI-guided adaptive radiotherapy with Elekta Unity improves patient-reported urinary symptoms in men with prostate cancer

Press release9/25/2025, 5:30 AM

Elekta marks two millionth patient treated with Leksell Gamma Knife radiosurgery

Regulatory press release9/8/2025, 5:30 AM

Elekta announces changes in Executive Management

Regulatory press release9/4/2025, 2:56 PM

Report from the Annual General Meeting 2025 of Elekta

Regulatory press release8/28/2025, 5:30 AM

Interim report, First quarter May–July 2025/26

Press release8/7/2025, 5:30 AM

Invitation to the presentation of Elekta’s first quarter 2025/26

Regulatory press release8/1/2025, 5:30 AM

Notice to the Annual General Meeting of Elekta AB (Publ)

Press release7/23/2025, 1:00 PM

Elekta receives U.S. FDA 510(k) clearance for its Gamma Knife radiosurgery system to treat patients with refractory, drug-resistant mesial temporal lobe epilepsy

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.